baccarat house edge
Unemployment throughout Washington state, including in Lewis County, spiked in November, according to the Washington State Employment Security Department (ESD). On Tuesday, the agency reported Lewis County had a 5.9% unemployment rate last month, up from the 4.8% the county reported in October. Across the state, the ESD reported the economy decreased by 35,900 jobs in November, though the statewide rate fell slightly to 4.7%. According to the U.S. Department of Labor, the unemployment rate nationwide sat at 4.2% in November, with 7.1 million people unemployed and 2.1 million filing for unemployment. According to the state ESD, the largest job gains statewide in the past year occurred in health services and social assistance, education and health services and government. Between October 2023 and October 2024, Washington lost 15,400 jobs in the private sector and added 32,100 jobs in government. Across Southwest Washington, Thurston County reported a 4.5% unemployment rate, Skamania County saw a rate of 5.2%, Pierce County reported a 5.1% rate, Cowlitz County saw a 5.3% rate, Grays Harbor County was at 6.9%, Pacific County was at 6.3% and Wahkiakum County was at 6.6%.Canadian investors are navigating investment options for a potentially explosive 2025. As the economy braces for a potential shock as the United States’s president-elect threatens to impose huge tariffs on trade partners, finding stocks that offer growth, reliable , and wealth preservation has become increasingly crucial. Enter ( ), a rare stock investment option that checks most boxes for investors. While high-flying tech stocks grab headlines, Fortis – an electric and gas utility stock serving millions of customers in Canada, the United States and Caribbean territories – has quietly built a 51-year track record of consecutive dividend increases, recently becoming only the second Canadian company to achieve the coveted status (behind ( ) stock). Its fresh 4.2% dividend raise in November brings the current yield to 4.1%, but here’s what makes Fortis stock truly compelling for 2025: For investors seeking the trifecta of steady income, capital preservation, and long-term growth potential, Fortis stock’s story is more than about the 4.1% future dividend yield. It demands more attention. A $26 billion growth plan powers Fortis stock’s future Fortis stock isn’t just about current income – it’s positioned for significant growth. The company’s newly announced 2025–2029 capital expenditure plan of $26 billion represents its most ambitious (and low-risk) expansion yet. This comprehensive revenue and earnings growth plan, which exceeds the previous five-year strategy by $1 billion, aims to grow the company’s rate base from $38.8 billion to approximately $53 billion by 2029, targeting a robust 6.5% annual growth rate. Revenue growth could translate into earnings, cash flow, and respectable dividend growth rates. How Fortis stock could double your money For investors seeking wealth accumulation, Fortis stock presents a compelling case. Using the predictive power of the , doubling your investment over a decade requires roughly 7.2% in annual total returns. Fortis stock’s current 4.1% dividend yield, combined with management’s targeted dividend growth rate of 4-6% through 2029, means investors need only modest share price appreciation to achieve this goal. Historical performance supports this potential – investors who purchased Fortis stock a decade ago and reinvested all dividends saw their position grow by 125%. data by Buy Fortis stock for stability in uncertain times What makes Fortis stock particularly valuable is its remarkable stability. With a one-year Beta of just 0.09 against the , Fortis stock has shown exceptionally low volatility compared to the broader market. As a regulated electric and gas utility serving millions of needy customers, Fortis provides essential services that generally remain in demand regardless of economic conditions. The growing energy demands of artificial intelligence (AI) and technological advancement provide additional tailwinds for Fortis stock’s growth trajectory. Interestingly, Fortis stock could help diversify volatile AI-tilted portfolios. Fortis stock’s attractive valuation and low-risk growth funding Currently trading at a forward price-to-earnings (P/E) multiple of 17.8, Fortis stock sits comfortably within its five-year historical PE range. This reasonable valuation, paired with the company’s proven track record of shareholder wealth creation, creates an appealing entry point for long-term investors. The company’s plans to fund its $26 billion capital expenditure primarily through internally generated cash flow, reduces the risk of excessive debt or equity dilution. Fortis’s dividend reinvestment plan (DRIP) provides an additional source of capital for future projects, and allows current investors to participate in its growth projects for even more dividends and capital gains. Fortis stock appears to be a well-positioned core-portfolio investment for 2025 and beyond. Investor takeaway For investors seeking a combination of current income, growth potential, and stability, Fortis stands out as a compelling choice. Its status as a dividend king, coupled with its robust growth plans and an essential business model, makes it a strong candidate for any growth and income-focused portfolios heading into 2025.Act fast! Keurig's iced coffee maker just went on sale for the first time in this Amazon Black Friday dealKey topics on the agenda included security assistance for Ukraine, economic support, and diplomatic strategies to counter Russian influence in the region. President Zelensky reportedly presented a comprehensive plan outlining Ukraine's priorities and expectations from its allies, with a particular emphasis on the need for increased military aid and a stronger stance against Russian aggression.
While the delay is undoubtedly disappointing, it is important to acknowledge the complexity of bringing new display technologies to market. The development of cutting-edge display technologies requires meticulous attention to detail, rigorous testing, and collaboration with suppliers and manufacturers. In this context, delays are not uncommon and are often necessary to ensure that the final product meets the highest standards of quality and performance.
Zelensky's decision to prioritize discussions with Biden over Trump reflects these changing dynamics and underscores Ukraine's desire to align itself more closely with Western democratic values and security frameworks. By engaging with the Biden administration on the issue of NATO membership, Zelensky aims to demonstrate Ukraine's commitment to Euro-Atlantic integration and its readiness to take on greater security responsibilities.Selena, the multi-talented pop sensation who has been stunning audiences with her music and acting skills, has secured nominations in the Best Female Artist and Best Original Song categories. With her powerful vocals and charismatic stage presence, Selena has become a force to be reckoned with in the music industry. Her nomination in the Best Original Song category further solidifies her place as a versatile and innovative artist.
The decision to rotate the squad comes as no surprise, as Conte has been known to carefully manage his players' fitness and workload throughout the season. With a packed schedule of domestic and European fixtures, it is imperative for Inter Milan to have a deep and versatile squad to stay competitive on all fronts. By rotating the squad, Conte aims to keep his players fresh and avoid injuries during this crucial stage of the season.As the football world continues to evolve and unfold, with its highs and lows, the story of the Guardiola brothers serves as a reminder that passion, dedication, and a touch of humor can go a long way in navigating the complexities of the beautiful game. Whether Pep Guardiola ever decides to heed his brother's playful suggestion and take on the challenge of managing Girona remains to be seen. But one thing is certain - the Guardiola brothers' bond and mutual admiration for each other will always remain a source of inspiration for football enthusiasts around the world.
Joe Biden's pardon of his son Hunter spurs broader discussion on who else should be granted clemency
One of the key reasons why the securities industry believes that real estate development and construction hold promise is the continuous urbanization trend. As more people move from rural areas to urban centers, the demand for residential, commercial, and infrastructure projects is on the rise. This trend not only presents opportunities for property developers but also for investors looking to capitalize on the growth potential of urban areas.
As the investigation unfolds, more complex layers begin to unravel, revealing surprising connections and hidden truths that challenge the villagers' preconceived notions and beliefs. It becomes evident that the young woman's past is far more enigmatic and intriguing than anyone could have imagined, raising questions about her true intentions and motivations.
CRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal full year ended September 30, 2024 . Fiscal Full Year 2024 Business Highlights and Subsequent Developments Financial Highlights "Reflecting on 2024, Citius Oncology has achieved pivotal milestones that underscore our commitment to advancing cancer therapeutics," stated Leonard Mazur , Chairman and CEO of Citius Oncology. "The FDA's approval of LYMPHIR for the treatment of cutaneous T-cell lymphoma marks a significant advancement in providing new options for patients battling this challenging disease. It is the only targeted systemic therapy approved for CTCL patients since 2018 and the only therapy with a mechanism of action that targets the IL-2 receptor. Additionally, the successful merger forming Citius Oncology, now trading on Nasdaq under the ticker CTOR, strengthens our position in the oncology sector. We expect it to facilitate greater access to capital to fund LYMPHIR's launch and the Company's future growth. With a Phase I investigator-initiated clinical trial combining LYMPHIR with pembrolizumab demonstrating promising preliminary results, indicating potential for enhanced treatment efficacy in recurrent solid tumors, and preliminary results expected from a second investigator trial with CAR-T therapies in 2025, we remain excited about the potential of LYMPHIR as a combination immunotherapy." "These accomplishments reflect the dedication of our team and the trust of our investors. As we look ahead, we remain steadfast in our mission to develop innovative therapies that improve the lives of cancer patients worldwide," added Mazur. FULL YEAR 2024 FINANCIAL RESULTS: Research and Development (R&D) Expenses R&D expenses were $4.9 million for the full year ended September 30, 2024 , compared to $4.2 million for the full year ended September 30, 2023 . The increase reflects development activities completed for the resubmission of the Biologics License Application of LYMPHIR in January 2024 , which were associated with the complete response letter remediation. General and Administrative (G&A) Expenses G&A expenses were $8.1 million for the full year ended September 30, 2024 , compared to $5.9 million for the full year ended September 30, 2023 . The increase was primarily due to costs associated with pre-commercial and commercial launch activities of LYMPHIR including market research, marketing, distribution and drug product reimbursement from health plans and payers. Stock-based Compensation Expense For the full year ended September 30, 2024 , stock-based compensation expense was $7.5 million as compared to $2.0 million for the prior year. The primary reason for the $5.5 million increase was due to the amounts being realized over 12 months in the year ended September 30, 2024 , as compared to three months post-plan adoption in the year ended September 30, 2023 . Net loss Net loss was $21.1 million , or ($0.31) per share for the year ended September 30, 2024 , compared to a net loss of $12.7 million , or ($0.19) per share for the year ended September 30, 2023 . The $8.5 million increase in net loss was primarily due to the increase in our operating expenses. About Citius Oncology, Inc. Citius Oncology specialty is a biopharmaceutical company focused on developing and commercializing novel targeted oncology therapies. In August 2024 , its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million , is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. Citius Oncology is a publicly traded subsidiary of Citius Pharmaceuticals. For more information, please visit www.citiusonc.com Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Oncology are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; risks related to research using our assets but conducted by third parties; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov , including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2024 , filed with the SEC on December 27, 2024 , as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investor Contact: Ilanit Allen ir@citiuspharma.com 908-967-6677 x113 Media Contact: STiR-communications Greg Salsburg Greg@STiR-communications.com -- Financial Tables Follow – CITIUS ONCOLOGY, INC. CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2024 AND 2023 2024 2023 Current Assets: Cash and cash equivalents $ 112 $ — Inventory 8,268,766 — Prepaid expenses 2,700,000 7,734,895 Total Current Assets 10,968,878 7,734,895 Other Assets: In-process research and development 73,400,000 40,000,000 Total Other Assets 73,400,000 40,000,000 Total Assets $ 84,368,878 $ 47,734,895 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 3,711,622 $ 1,289,045 License payable 28,400,000 — Accrued expenses — 259,071 Due to related party 588,806 19,499,119 Total Current Liabilities 32,700,429 21,047,235 Deferred tax liability 1,728,000 1,152,000 Note payable to related party 3,800,111 — Total Liabilities 38,228,540 22,199,235 Stockholders' Equity: Preferred stock - $0.0001 par value; 10,000,000 shares authorized: no shares issued and outstanding — — Common stock - $0.0001 par value; 100,000,000; 71,552,402 and 67,500,000 shares issued and outstanding at September 30, 2024 and 2023, respectively 7,155 6,750 Additional paid-in capital 85,411,771 43,658,750 Accumulated deficit (39,278,587) (18,129,840) Total Stockholders' Equity 46,140,339 25,535,660 Total Liabilities and Stockholders' Equity $ 84,368,878 $ 47,734,895 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Revenues $ — $ — Operating Expenses: Research and development 4,925,001 4,240,451 General and administrative 8,148,929 5,915,290 Stock-based compensation – general and administrative 7,498,817 1,965,500 Total Operating Expenses 20,572,747 12,121,241 Loss before Income Taxes (20,572,747) (12,121,241) Income tax expense 576,000 576,000 Net Loss $ (21,148,747) $ (12,697,241) Net Loss Per Share – Basic and Diluted $ (0.31) $ (0.19) Weighted Average Common Shares Outstanding – Basic and Diluted 68,053,607 67,500,000 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Cash Flows From Operating Activities: Net loss $ (21,148,747) $ (12,697,241) Adjustments to reconcile net loss to net cash provided by operating activities: Stock-based compensation expense 7,498,817 1,965,500 Deferred income tax expense 576,000 576,000 Changes in operating assets and liabilities: Inventory (2,133,871) - Prepaid expenses (1,100,000) (5,044,713) Accounts payable 2,422,577 1,196,734 Accrued expenses (259,071) (801,754) Due to related party 14,270,648 14,805,474 Net Cash Provided By Operating Activities 126,353 - Cash Flows From Investing Activities: License payment (5,000,000) - Net Cash Used In Investing Activities (5,000,000) - Cash Flows From Financing Activities: Cash contributed by parent 3,827,944 - Merger, net (2,754,296) - Proceeds from issuance of note payable to related party 3,800,111 - Net Cash Provided By Financing Activities 4,873,759 - Net Change in Cash and Cash Equivalents 112 - Cash and Cash Equivalents – Beginning of Year - - Cash and Cash Equivalents – End of Year $ 112 $ - Supplemental Disclosures of Cash Flow Information and Non-cash Activities: IPR&D Milestones included in License Payable $ 28,400,000 $Asteroid nearly hits Earth in Siberia, with a 2nd massive asteroid passing this weekIn the wake of this tragedy, questions have been raised about the availability and regulation of 3D printed firearms, as well as the mental health and motivations of individuals capable of such violent acts. The intersection of technology, education, and criminal behavior has cast a spotlight on the need for greater vigilance and preventative measures to ensure the safety and security of our communities.
EAST RUTHERFORD, N.J. (AP) — Indianapolis quarterback Anthony Richardson has been ruled out for the Colts' big game at the New York Giants on Sunday. Richardson missed practice on Thursday and Friday because of back and foot injuries. He was listed as questionable before he was downgraded to out on Saturday. Indianapolis (7-8) has a slim chance of making the playoffs. The Colts need to win out and get some help. Richardson's absence likely means Joe Flacco will start against New York. Flacco, a New Jersey native who turns 40 on Jan. 16, has passed for 1,167 yards and nine touchdowns in six games this season, including four starts. He also has thrown five interceptions. The 22-year-old Richardson was selected by Indianapolis with the No. 4 pick in the 2023 draft. He has passed for 1,814 yards and eight touchdowns with 12 interceptions this year. AP NFL: https://apnews.com/hub/nflIn a world filled with uncertainty and doubt, the simple act of a graduate visiting his former teacher brought a sense of peace and reassurance, a reminder that kindness, dedication, and perseverance can truly make a difference in someone's life. And as the night descended and the stars twinkled overhead, Mrs. Zhang knew that her efforts as an educator had not been in vain, that her legacy would live on in the hearts of her students, including the brave young man who had once walked through her classroom door with a dream in his eyes.One of the key factors in effective science communication, according to Dr. Zhang, is storytelling. By weaving narratives and anecdotes into her presentations and articles, she is able to capture the audience's interest and make scientific topics come alive. "Stories have a way of connecting people on an emotional level and making information more memorable," she explained. "By framing scientific concepts within a narrative structure, we can create a shared experience that resonates with people."
LUBADDE RAHIM: Curbing Urban Sprawl: A Call to Action for Real Estate Companies
Watch out for fake Ryzen 9800X3D listings and don't get scammed
In a significant shift from the previous administration's approach to Syria, President Joe Biden has declared that the United States will engage with all Syrian groups in an effort to help facilitate a peaceful transition in the war-torn country. This bold statement marks a new chapter in America's involvement in the Syrian conflict and embodies a commitment to diplomacy and constructive engagement.As Lang Ping celebrates another year of life, her legacy continues to inspire a new generation of athletes and fans. Her passion for the game, her relentless pursuit of excellence, and her unwavering commitment to her players have made her a role model for aspiring athletes everywhere. Her impact extends far beyond the volleyball court, serving as a shining example of what can be achieved through determination, resilience, and teamwork.